APA (7th ed.) Citation

C, N., WY, J., M, O., S, D. M., C, S., SS, Y., . . . WJ, C. (2025). A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM). Blood cancer journal, 15(1), 109. https://doi.org/10.1038/s41408-025-01296-8

Chicago Style (17th ed.) Citation

C, Nagarajan, et al. "A Phase 2 Study of Daratumumab with Thalidomide and Dexamethasone in Relapsed And/or Refractory Myeloma (RRMM)." Blood Cancer Journal 15, no. 1 (2025): 109. https://doi.org/10.1038/s41408-025-01296-8.

MLA (9th ed.) Citation

C, Nagarajan, et al. "A Phase 2 Study of Daratumumab with Thalidomide and Dexamethasone in Relapsed And/or Refractory Myeloma (RRMM)." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 109, https://doi.org/10.1038/s41408-025-01296-8.